NNNN
NASDAQ · Biotechnology
Anbio Biotechnology Ltd
$5.58
-0.10 (-1.76%)
Financial Highlights (FY 2026)
Revenue
29.42M
Net Income
21.78M
Gross Margin
87.2%
Profit Margin
74.1%
Rev Growth
-28.4%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 87.2% | 87.2% | 30.8% | 30.8% |
| Operating Margin | 66.7% | 60.0% | -15.2% | -16.7% |
| Profit Margin | 74.1% | 70.4% | -19.2% | -20.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 29.42M | 41.08M | 1.84B | 1.79B |
| Gross Profit | 25.67M | 35.84M | 567.81M | 552.88M |
| Operating Income | 19.62M | 24.66M | -280,071,476 | -300,415,133 |
| Net Income | 21.78M | 27.38M | -354,337,532 | -367,227,211 |
| Gross Margin | 87.2% | 87.2% | 30.8% | 30.8% |
| Operating Margin | 66.7% | 60.0% | -15.2% | -16.7% |
| Profit Margin | 74.1% | 70.4% | -19.2% | -20.5% |
| Rev Growth | -28.4% | -28.4% | +17.6% | +11.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 886.33M | 752.45M |
| Total Equity | — | — | 1.73B | 1.94B |
| D/E Ratio | — | — | 0.51 | 0.39 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 19.63M | 26.04M | -454,323,212 | -381,836,603 |
| Free Cash Flow | — | — | -249,462,362 | -276,575,086 |